KDR and renal cell carcinoma: In the phase 3, randomized METEOR trial (ClinicalTrials.gov Identifier: NCT01865747), treatment with cabozantinib improved progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) were compared with treatment with everolimus in patients with metastatic RCC who were treated with at least one prior VEGFR-TKI [14].